Cyclobenzaprine hydrochloride - Tonix Pharmaceuticals
Alternative Names: Cyclobenzaprine HCL - Tonix Pharmaceuticals; cyclobenzaprine HCl sublingual tablet - Tonix Pharmaceuticals; KRL-102; TNX-102; TNX-102 SL; TNX-102 SL1; Tonmya; VLD-cyclobenzaprineLatest Information Update: 24 Sep 2026
At a glance
- Originator Vela Pharmaceuticals
- Developer Tonix Pharmaceuticals Holding Corp
- Class Amines; Antidepressants; Anxiolytics; Behavioural disorder therapies; Dibenzocycloheptenes; Drug withdrawal therapies; Muscle relaxants; Non-opioid analgesics; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Histamine H1 receptor antagonists; Muscarinic M1 receptor antagonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Fibromyalgia
- Phase III Post-traumatic stress disorders
- Phase II Acute traumatic stress disorders; Major depressive disorder
- Suspended Agitation; Alcoholism; Post acute COVID 19 syndrome
Most Recent Events
- 22 Sep 2026 Tonix Pharmaceuticals plans to initiate a phase II trial of TNX 102 SL in Acute stress disorder and Acute stress reaction
- 15 Apr 2026 Pharmacokinetics and adverse events data from a phase I trial in Healthy volunteers released by Tonix Pharmaceuticals
- 18 Mar 2026 Phase-II clinical trials in Major depressive disorder (Treatment-naive, Monotherapy) in USA (Sublingual) prior to March 2026 (NCT07621237)